<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231646</url>
  </required_header>
  <id_info>
    <org_study_id>10-266A</org_study_id>
    <nct_id>NCT01231646</nct_id>
  </id_info>
  <brief_title>Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?</brief_title>
  <official_title>Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epilepsy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth
      to infant with certain birth defects. However, some medications may affect the action of
      folate. The purpose of this study is to compare the effect of two anti-epileptic drugs on how
      folate works in our body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of Folate Receptor Autoantibodies</measure>
    <time_frame>On the same day after informed consent was obtained</time_frame>
    <description>ELISA assays using immobilized folate receptor protein were performed to determine the titers of immunoglobulin G, immunoglobulin M, and combined immunoglobulin G and immunoglobulin M to folate receptor in serum samples collected from both groups of women.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Epilepsy</condition>
  <condition>Psychiatric or Mood Diseases or Conditions</condition>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention. This is a cross-sectional study.</description>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_label>Valproate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in epilepsy and/or psychiatric clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ages 18-50 years inclusive who are taking valproate or lamotrigine for
             neurologic or psychiatric conditions

          -  Valproate of lamotrigine must be used as monotherapy at stable doses for 6 weeks prior
             to the study for the neurologic or psychiatric illness; medications taken for other
             reasons are not excluded.

        Exclusion Criteria:

          -  Women with prior exposure to valproate or lamotrigine if they are taking lamotrigine
             or valproate respectively.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Harden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore-Long Island Jewish Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <results_first_submitted>August 24, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2015</results_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Folate Receptor Autoantibodies</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Psychiatric conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lamotrigine</title>
          <description>Women on lamotrigine monotherapy or polytherapy, and had never been exposed to valproate.</description>
        </group>
        <group group_id="P2">
          <title>Valproate</title>
          <description>Women on valproate monotherapy or polytherapy, and had never been exposed to lamotrigine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lamotrigine</title>
          <description>Women on lamotrigine monotherapy or polytherapy, and had never been exposed to valproate.</description>
        </group>
        <group group_id="B2">
          <title>Valproate</title>
          <description>Women on valproate monotherapy or polytherapy, and had never been exposed to lamotrigine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="10.22"/>
                    <measurement group_id="B2" value="39.1" spread="7.77"/>
                    <measurement group_id="B3" value="34.7" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.95" spread="4.3"/>
                    <measurement group_id="B2" value="30.47" spread="7.2"/>
                    <measurement group_id="B3" value="26.44" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of Folate Receptor Autoantibodies</title>
        <description>ELISA assays using immobilized folate receptor protein were performed to determine the titers of immunoglobulin G, immunoglobulin M, and combined immunoglobulin G and immunoglobulin M to folate receptor in serum samples collected from both groups of women.</description>
        <time_frame>On the same day after informed consent was obtained</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Women on lamotrigine monotherapy or polytherapy, and had never been exposed to valproate.</description>
          </group>
          <group group_id="O2">
            <title>Valproate</title>
            <description>Women on valproate monotherapy or polytherapy, and had never been exposed to lamotrigine.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Folate Receptor Autoantibodies</title>
          <description>ELISA assays using immobilized folate receptor protein were performed to determine the titers of immunoglobulin G, immunoglobulin M, and combined immunoglobulin G and immunoglobulin M to folate receptor in serum samples collected from both groups of women.</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immunoglobulin G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.33" spread="27.14"/>
                    <measurement group_id="O2" value="35.21" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="34.18"/>
                    <measurement group_id="O2" value="41.81" spread="33.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin G and Immunoglobulin M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.62" spread="50.12"/>
                    <measurement group_id="O2" value="77.06" spread="46.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a cross-sectional 1 visit study. No Adverse Event were collected or assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lamotrigine</title>
          <description>Women on lamotrigine monotherapy or polytherapy, and had never been exposed to valproate.</description>
        </group>
        <group group_id="E2">
          <title>Valproate</title>
          <description>Women on valproate monotherapy or polytherapy, and had never been exposed to lamotrigine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Connie Lau, MS, CCRC</name_or_title>
      <organization>North Shore-LIJ Health System</organization>
      <phone>516-325-7022</phone>
      <email>clau@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

